Yüklüyor......
Natalizumab: A new treatment for relapsing remitting multiple sclerosis
Natalizumab, a new disease-modifying therapy for relapsing remitting multiple sclerosis (RRMS), is a humanized monoclonal antibody which binds to α(4)β(1)-integrin. In a Phase 3 trial, 2 years of natalizumab monotherapy reduced the mean annualized relapse rate (ARR) by 68% compared with placebo (p &...
Kaydedildi:
| Yazar: | |
|---|---|
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
Dove Medical Press
2007
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC1936307/ https://ncbi.nlm.nih.gov/pubmed/18360634 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|